Pfizer Inc. is set to announce its latest quarterly earnings on Monday, May 4th, with a consensus estimated EPS of 0.74.
Pfizer Inc.'s current price stands at $26.72, showing a decrease of 6.89 cents (-0.257%) from the previous close. The trading volume is at $24.12 million, 58.72% relative to the average.
The company's latest quarterly earnings were reported on Monday, February 2nd, with a consensus EPS estimate of 0.57.
Pfizer Inc. offers a forward dividend yield of 6.44%, with a dividend per share of 43 cents and a trailing twelve months dividend per share of $1.72.
The company's free cash flow stands at $4.50 billion, with notable activities including acquisitions netting -$6.93 billion and debt repayment of -$3 billion.
Pfizer Inc. reported a revenue of $17.56 billion, generating a gross profit of $12.29 billion. The company faced a net loss of $1.65 billion, translating to an EPS of -29 cents.
Key financial ratios include a gross profit margin of 69.97%, operating profit margin of 21%, and a return on equity of -1.91%.
The company holds total assets of $208.16 billion, with total liabilities amounting to $121.39 billion. Pfizer Inc. maintains a net debt of $66.27 billion.
This financial snapshot provides insights into Pfizer Inc.'s recent performance and financial position, offering investors valuable information for their decision-making process.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.